04 September 2018
A new report by visiongain predicts that the Global Drug Delivery Technologies market will reach $259.1bn in 2020. This forecast and others appear in Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes—published in July 2016. Visiongain is a business information provider based in London, UK.
Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report examines the current and future trends in the growing drug delivery technologies market. As the generic drug industry continues to see rapid growth, big pharma companies will continue to strive for extensions on their product life-cycles. Drug delivery technologies are of high demand not only because of the deep interest shown by pharma companies in recent years but also the dire need to improve patient compliance. Yemi Adebayo, a Pharmaceutical and Medical Devices Analyst at visiongain comments:
“Drug delivery technologies provide ample opportunities for both biopharmaceutical companies that offer services providing new technologies and pharmaceutical companies attempting to extend the product lifecycle of their product. The drug delivery technologies market will see fast growth over the next ten years. The oral drug delivery market remains the most dominant submarket, which is largely due to the convenience of taking drugs orally. However, with increasing numbers of biologic medicines we expect to see the injectable drug delivery tech market grow rapidly over the forecast period. The problem with using the parenteral route for drug delivery is the inconvenience it brings to patients. As such, novel ways of administering biologics will be sought. This, together with the growing burden of an ageing population and rise in chronic diseases in most developed countries will continue to cause demand for new ways of delivering drugs to their intended target.”
In this report, we examine in detail the drug delivery technologies market, and provide analyses and forecasts for regional and national markets. Historical revenues have also been added to strengthen our analysis to demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.
Visiongain’s report provides revenue forecasts to 2026 for the global biologics market, the global vaccines market and the global drug delivery technologies market and the leading regional and national drug delivery technologies markets. The report discusses selected leading companies in the market. These companies include Alkermes, 3M, Skyepharma, Becton Dickinson and Company (BD), Antares Pharma, pSivida, Applied Pharma Research (APR), Ethypharm, Glycologic and NanoPass Technologies
Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on email@example.com
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 61
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional that needs independent, high quality, original analyses to inform their strategic decisions.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.